AEON Biopharma, Inc. ASE · AEON
Price alert —
Sign in to get a one-time email the moment AEON crosses your price. Free accounts included.
Sign in / create a free accountAEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins.
AEON last traded at $0.29, down 0.7% on the day; that's in the lower part of its 52-week range ($0.26–$1.45). Right now it's stretched well below its recent average — historically the kind of washed-out level where bounces tend to start.
Earnings reports are the biggest scheduled catalysts to keep an eye on, and after the recent dip, watch whether the price stops making lower lows before assuming the worst is over.
A plain-English snapshot built from the data on this page — not investment advice. Always do your own research.
KC3 lower (deep stretch), -3.72 ATR from EMA21 — no notable pattern
- · KC3 lower stretch — deepest mean-reversion tier
- · Counter-trend long in breakout down
Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.
- · Stochastic bear cross
- · Aligned with breakout down (strong tailwind)
Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.
AEON is a $13 million company, it moves more calmly than the market (beta 0.6), and the stock is trading near the bottom of its 52-week range.
Earnings
See more →- Last reported
- 2026-05-14
- EPS (act / est)
- -0.25 / -0.44
- Surprise
- +44.2%
About
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine. It also develops ABP-450 for the…